Qanatpharma, Zuse Institute Berlin, Enamine, and Proteros biostructures Announce Generative-AI Driven Lead Discovery Collaboration
An international discovery collaboration is harnessing AI-powered drug discovery to develop a first-in-class therapy to prevent delayed cerebral ischemia in patients with subarachnoid hemorrhage. The program sets a precedent for the use of generative AI technologies in accelerating early-stage drug discovery for cerebrovascular conditions.
STANS, Switzerland and TORONTO and MUNICH and BERLIN and KYIV, Ukraine, July 09, 2025 (GLOBE NEWSWIRE) --
Qanatpharma (QP), Zuse Institute Berlin (ZIB), Enamine, and Proteros biostructures today announced the launch of a research collaboration to accelerate the discovery of novel therapeutics targeting cerebral perfusion deficits associated with subarachnoid hemorrhage (SAH). The collaboration focuses on a protein target identified by QP that is involved in regulating cerebrovascular resistance in the brain—a mechanism shown to be compromised in patients with SAH.
This program spans the drug discovery and development process from early generative molecular design and docking studies done by the ZIB developing its proprietary algorithms, via the REAL®-directed compound synthesis by Enamine, the world's largest supplier of make-on-demand small molecules, to the validation of hit compounds by Proteros using their structure-based drug discovery platform.
Targeting a Critical Unmet Need in Stroke Recovery
Subarachnoid hemorrhage is a severe form of stroke caused by bleeding into the space surrounding the brain. A leading complication in SAH survivors is delayed cerebral ischemia (DCI), a condition that reduces cerebral perfusion and significantly contributes to long-term neurological damage, disability, and death. Current treatment options are largely ineffective. Nimodipine, a calcium channel blocker currently approved as a standard of care for SAH, fails to target the molecular mechanism underlying DCI presumably explaining its limited clinical efficacy.
Together, the partners of this collaboration combine detailed insights into the microvascular nature of cerebrovascular complications with computational innovation, medicinal chemistry, protein sciences, biophysics, biochemistry, and structural biology, including cryo-EM, to develop targeted small molecule lead candidates. QP initiated the collaboration to develop its well-characterized cerebrovascular target into an innovative therapy. ZIB brings deep expertise in high-performance computing, ligand docking, and AI-based generative ligand design. Enamine's unique key to access ultra-large chemical space via the REAL® approach, its unparalleled compound libraries and synthesis capabilities allow rapid translation of virtual hits into real novel chemical matter. Proteros leverages its drug discovery platform to deliver structurally enabled Qualified Hits Lead Series with fully characterized Mode-of-Action enabling downstream Lead Optimization and pre-clinical development.
'Delayed cerebral ischemia is a major contributor to poor outcomes following subarachnoid hemorrhage, and current treatment options remain limited,' said Dr. Steffen-Sebastian Bolz, Chief Medical and Scientific Officer at Qanatpharma. 'By building this consortium, we are bringing together the brightest machine learning engineers, chemists, structural biologists, and other scientists to tackle this critical complication. Together, we aim to accelerate the development of a targeted therapy that could significantly improve recovery and long-term outcomes for patients affected by SAH.'
DSc. Yurii Moroz, Vice President of Sales and Marketing, Enamine: 'Our consortium with strong complementary expertise leverages the challenging opportunity to navigate towards the most suitable first-in class drug candidate by pushing the limits of accessible chemical space,' and Dr. Sven H. Wagner, Vice President of Partnerships at Enamine Germany said 'Enamine underscores with our consortium its partnership commitment translating critical discoveries without delay, with highest scientific rigor and under challenging funding bottlenecks into life-saving medicines for patients with high unmet medical need such as with conditions of delayed cerebral ischemia with SAH.'
'We are pleased about this collaboration aiming to address a drug target identified by QP which could transform the treatment of life-threatening complications,' said Dr Torsten Neuefeind, founder and CEO of Proteros.
Next Steps and Outlook
This multiparty collaboration has already initiated compound screening efforts and will proceed to in vitro validation studies in the second half of 2025. This marks the most significant effort so far towards understanding and ultimately treating diseases driven by microvascular dysfunction with innovative compounds. The program sets a precedent for the use of generative AI technologies in accelerating early-stage drug discovery for cerebrovascular conditions. Stakeholders and researchers interested in collaboration or progress updates are invited to follow the project via QP's website or contact the collaborators directly.
Company Summaries:
About Qanatpharma AG
Qanatpharma (QP) is a Phase 2 clinical-stage biopharma company developing innovative therapies for diseases where microvascular dysfunction is a central feature. QP manages a pipeline that spans from microvascular target discovery and validation via AI-driven drug development to preclinical studies and, ultimately, clinical trials. For more information, please visit www.qanatpharma.com
About Zuse Institute Berlin
The Zuse-Institute Berlin (ZIB) is an interdisciplinary research institute for applied mathematics and data-intensive high-performance computing. Its research focuses on modeling, simulation and optimization with scientific cooperation partners from academia and industry. For more information, please visit www.zib.de
About Enamine Ltd.
Enamine is the leading provider of chemical compounds and a scientifically driven integrated discovery Contract Research Organisation for integrated discovery with unique partnering opportunities in exploring new chemical space. The company combines access to the in-house produced screening compounds (4.5M in stock) and building blocks (350K in stock) with a comprehensive platform of integrated discovery services in bioinformatics, biology, and chemistry to advance and accelerate the efforts in drug discovery. For more information, please visit: enamine.net/
About Proteros biostructures GmbH
Proteros is a structure-based drug discovery provider with cutting edge platform to unlock even the most technically challenging drug targets.
For more information, please visit www.proteros.com
Contact Information
For Qanatpharma:
Dr. Philipp Trepte
Managing Director Qanatpharma Germany GmbH
Phone: +49 152 08734310
Email: [email protected]
For Zuse Institute Berlin:
Dr. Christopher Secker
Project lead for the Zuse Institute
Phone: +49 30 84185-386
Email: [email protected]
For Enamine:
DSc. Yurii Moroz
Vice President of Sales and Marketing
Email: [email protected]
For Proteros biostructures:
Dr. Debora Konz Makino
VP Business Unit Hit & Lead Finding
Phone: +49 89 700761-0
Email: [email protected]
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
16-07-2025
- Business Wire
Orogen Therapeutics and Chemspace/Enamine Announce a Strategic Collaboration to Enable Unique REAL-Driven DNA Encoded Small Molecule Libraries
WOBURN, Mass. & KYIV, Ukraine--(BUSINESS WIRE)--Orogen Therapeutics, Inc., a private drug discovery company utilizing its proprietary, AI-enabled DNA encoded library (DEL) technology to identify novel chemical matter against medically and commercially attractive drug targets, Chemspace, LLC, an expert in the generation and exploration of ultra-large chemical datasets, and Enamine, Ltd., a leading worldwide provider of chemical compounds and drug discovery services, announced today a strategic collaboration to design, build, and test novel DNA-encoded libraries (DEL) leveraging Chemspace's chemi-informatics and synthetic capabilities and Enamine's REAL design principles, combined with Orogen's deep DEL expertise, and proprietary AI- and DEL-enabled small molecule drug discovery capabilities. Enamine's REAL compounds are the world's largest collection of make-on-demand small molecules that represents a significant fraction of the synthetically accessible chemical space. Its member molecules are REadily AccessibLe through validated parallel synthesis protocols using qualified in-stock building blocks. Orogen's DEL- and AI-enabled platform, including FocusDEL™ technology, enables rapid, efficient drug screening of billions of chemically diverse compounds to effectively home in on small drug-like molecules against specific targets from a wide range of therapeutic areas and clinical indications. 'We are thrilled to engage in this strategic collaboration to drive new horizons for DEL-based drug development that brings together this powerful combination of technologies – Chemspace-Enamine's vast REAL Space of innovative chemical matter and Orogen's AI- and DEL-enabled small molecule drug discovery platform - to advance a new generation in DEL capability,' stated Mark Pykett, Orogen CEO. 'We are excited by the potential synergy of the two platforms to enhance and accelerate small molecule drug discovery.' "DNA-encoded library (DEL) screening offers a proven valuable alternative for sampling large chemical space for efficient small molecule drug discovery,' stated Sven Wagner, PhD, Vice President of Partnerships at Enamine. 'We are pleased to bring our large and rapidly synthesizable Chemspace/Enamine chemical space into this collaboration with Orogen, a pioneer in DEL-based drug discovery, leveraging AI-enabled DELs. Our dovetailing joint effort will enrich DEL-based drug R&D with a critical component and a large part of chemical space, ready to be mined by researchers around the world, ultimately to enable sooner than later treatments for patients with high unmet needs across therapeutic areas, such as immuno-inflammatory disorders." Under the terms of the collaboration, Chemspace and Orogen will design novel DELs in alignment with the REAL Space foundational principles; Chemspace and Enamine will synthesize and analytically validate these REAL-driven DELs, and Orogen will screen pilot DELs against multiple biological targets. Chemspace and Enamine anticipate the opportunity to provide these libraries to enhance their array of product and service offerings, while Orogen envisions opportunities for multiple novel small molecule candidates aligned with its areas of focus in immuno-inflammatory disorders, GPCRs, and select oncology targets. Artem Evdokimov, PhD, Orogen's head of research, noted, 'We anticipate this collaboration will add a set of much-needed next-generation DELs to the arsenal of early drug discovery tools. Harmonization of DEL designs with REAL space chemistry enables rapid follow-up on screening: off-DNA compounds and thousands of their SAR-expanding chemical space neighbors can be made both expeditiously and economically – accelerating the early discovery process for much-needed novel, safe, and effective medicines.' Olga Tarkhanova, PhD, CEO of Chemspace: 'DEL technology is a powerful approach for efficiently exploring vast chemical space, enabling rapid hit identification, structure-activity relationship (SAR) development, and the discovery of novel binding sites. We are excited to join forces with Orogen, a leader in DEL-based drug discovery, to bring the Chemspace/Enamine chemical space into next-generation DEL design. With this collaboration, we bring the benefits of scalable, make-on-demand combinatorial chemistry to the DEL field, addressing a key bottleneck in moving from encoded hits to optimized compounds. By applying the REAL Space concept to DELs and integrating our proven Make-On-DEmand chemistry, this collaboration aims to simplify off-DNA hit synthesis and optimization, accelerate DMTA (design–make–test–analyze) cycles, and help advance new therapies.' About Orogen Therapeutics Orogen Therapeutics' mission is to deliver groundbreaking clinical solutions to patients with serious unmet medical needs. The company is revolutionizing small-molecule drug discovery through its proprietary platform integrating DNA-encoded libraries (DEL) with massive chemical diversity of billions of compounds, virtual screening and AI-driven computation. The company's proprietary, one-of-a-kind target-specific FocusDEL ™ (patent pending) seeks to innovate the DEL landscape by enabling enriched hit yields from immense chemical spaces. This unique foundation is designed to enable the efficient derivation of novel drug candidates against a broad range of target classes. Orogen's team includes scientists with decades of drug development experience and deep expertise in all aspects of small-molecule R&D, including DNA-encoded libraries, target selection and evaluation, cutting-edge AI and data science. For more information, please visit: About Chemspace Chemspace is a global provider of drug discovery services. We can streamline hit finding by integrating our Computational Chemistry tools, Bioinformatics, and Machine Learning-based services for smarter drug discovery. By exploring ultra-large chemical spaces, we deliver high-quality hit molecules for discovery projects. Our integrated projects combine hit identification services with biological validation, providing a seamless path from hit identification to pre-clinical studies. For more information, please visit: About Enamine Enamine is the leading provider of chemical compounds and a scientifically driven integrated discovery Contract Research Organisation for integrated discovery with unique partnering opportunities in exploring new chemical space. The company combines access to the in-house produced screening compounds (>> (350K in stock) with a comprehensive platform of integrated discovery services in bioinformatics, biology, and chemistry to advance and accelerate the efforts in drug discovery. For more information, please visit: Forward-Looking Statements 'Forward-looking statements' that may be contained in this communication are made within the meaning of federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future performance, and often contain words such as 'expect,' 'anticipate,' 'should,' 'hope,' 'project,' 'estimate,' 'predict,' 'goals,' 'intend,' 'plan,' 'believe,' 'seek,' 'will,' 'would,' 'target, 'outlook,' and similar expressions and variations or negatives of these words. All statements, other than those of historical fact, are forward-looking statements, including statements regarding outlook, expectations and guidance. Forward-looking statements address matters that are uncertain and subject to risks, uncertainties, and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements.
Associated Press
09-07-2025
- Associated Press
Qanatpharma, Zuse Institute Berlin, Enamine, and Proteros biostructures Announce Generative-AI Driven Lead Discovery Collaboration
Joint research program targets new treatments for life-threatening complication of brain hemorrhage An international discovery collaboration is harnessing AI-powered drug discovery to develop a first-in-class therapy to prevent delayed cerebral ischemia in patients with subarachnoid hemorrhage. The program sets a precedent for the use of generative AI technologies in accelerating early-stage drug discovery for cerebrovascular conditions. STANS, Switzerland and TORONTO and MUNICH and BERLIN and KYIV, Ukraine, July 09, 2025 (GLOBE NEWSWIRE) -- Qanatpharma (QP), Zuse Institute Berlin (ZIB), Enamine, and Proteros biostructures today announced the launch of a research collaboration to accelerate the discovery of novel therapeutics targeting cerebral perfusion deficits associated with subarachnoid hemorrhage (SAH). The collaboration focuses on a protein target identified by QP that is involved in regulating cerebrovascular resistance in the brain—a mechanism shown to be compromised in patients with SAH. This program spans the drug discovery and development process from early generative molecular design and docking studies done by the ZIB developing its proprietary algorithms, via the REAL®-directed compound synthesis by Enamine, the world's largest supplier of make-on-demand small molecules, to the validation of hit compounds by Proteros using their structure-based drug discovery platform. Targeting a Critical Unmet Need in Stroke Recovery Subarachnoid hemorrhage is a severe form of stroke caused by bleeding into the space surrounding the brain. A leading complication in SAH survivors is delayed cerebral ischemia (DCI), a condition that reduces cerebral perfusion and significantly contributes to long-term neurological damage, disability, and death. Current treatment options are largely ineffective. Nimodipine, a calcium channel blocker currently approved as a standard of care for SAH, fails to target the molecular mechanism underlying DCI presumably explaining its limited clinical efficacy. Together, the partners of this collaboration combine detailed insights into the microvascular nature of cerebrovascular complications with computational innovation, medicinal chemistry, protein sciences, biophysics, biochemistry, and structural biology, including cryo-EM, to develop targeted small molecule lead candidates. QP initiated the collaboration to develop its well-characterized cerebrovascular target into an innovative therapy. ZIB brings deep expertise in high-performance computing, ligand docking, and AI-based generative ligand design. Enamine's unique key to access ultra-large chemical space via the REAL® approach, its unparalleled compound libraries and synthesis capabilities allow rapid translation of virtual hits into real novel chemical matter. Proteros leverages its drug discovery platform to deliver structurally enabled Qualified Hits Lead Series with fully characterized Mode-of-Action enabling downstream Lead Optimization and pre-clinical development. 'Delayed cerebral ischemia is a major contributor to poor outcomes following subarachnoid hemorrhage, and current treatment options remain limited,' said Dr. Steffen-Sebastian Bolz, Chief Medical and Scientific Officer at Qanatpharma. 'By building this consortium, we are bringing together the brightest machine learning engineers, chemists, structural biologists, and other scientists to tackle this critical complication. Together, we aim to accelerate the development of a targeted therapy that could significantly improve recovery and long-term outcomes for patients affected by SAH.' DSc. Yurii Moroz, Vice President of Sales and Marketing, Enamine: 'Our consortium with strong complementary expertise leverages the challenging opportunity to navigate towards the most suitable first-in class drug candidate by pushing the limits of accessible chemical space,' and Dr. Sven H. Wagner, Vice President of Partnerships at Enamine Germany said 'Enamine underscores with our consortium its partnership commitment translating critical discoveries without delay, with highest scientific rigor and under challenging funding bottlenecks into life-saving medicines for patients with high unmet medical need such as with conditions of delayed cerebral ischemia with SAH.' 'We are pleased about this collaboration aiming to address a drug target identified by QP which could transform the treatment of life-threatening complications,' said Dr Torsten Neuefeind, founder and CEO of Proteros. Next Steps and Outlook This multiparty collaboration has already initiated compound screening efforts and will proceed to in vitro validation studies in the second half of 2025. This marks the most significant effort so far towards understanding and ultimately treating diseases driven by microvascular dysfunction with innovative compounds. The program sets a precedent for the use of generative AI technologies in accelerating early-stage drug discovery for cerebrovascular conditions. Stakeholders and researchers interested in collaboration or progress updates are invited to follow the project via QP's website or contact the collaborators directly. Company Summaries: About Qanatpharma AG Qanatpharma (QP) is a Phase 2 clinical-stage biopharma company developing innovative therapies for diseases where microvascular dysfunction is a central feature. QP manages a pipeline that spans from microvascular target discovery and validation via AI-driven drug development to preclinical studies and, ultimately, clinical trials. For more information, please visit About Zuse Institute Berlin The Zuse-Institute Berlin (ZIB) is an interdisciplinary research institute for applied mathematics and data-intensive high-performance computing. Its research focuses on modeling, simulation and optimization with scientific cooperation partners from academia and industry. For more information, please visit About Enamine Ltd. Enamine is the leading provider of chemical compounds and a scientifically driven integrated discovery Contract Research Organisation for integrated discovery with unique partnering opportunities in exploring new chemical space. The company combines access to the in-house produced screening compounds (4.5M in stock) and building blocks (350K in stock) with a comprehensive platform of integrated discovery services in bioinformatics, biology, and chemistry to advance and accelerate the efforts in drug discovery. For more information, please visit: About Proteros biostructures GmbH Proteros is a structure-based drug discovery provider with cutting edge platform to unlock even the most technically challenging drug targets. For more information, please visit Contact Information For Qanatpharma: Dr. Philipp Trepte Managing Director Qanatpharma Germany GmbH Phone: +49 152 08734310 Email: [email protected] For Zuse Institute Berlin: Dr. Christopher Secker Project lead for the Zuse Institute Phone: +49 30 84185-386 Email: [email protected] For Enamine: DSc. Yurii Moroz Vice President of Sales and Marketing Email: [email protected] For Proteros biostructures: Dr. Debora Konz Makino VP Business Unit Hit & Lead Finding Phone: +49 89 700761-0 Email: [email protected]
Time Business News
30-06-2025
- Time Business News
AI‑QUAL: The New AI Tool That Makes Prostate MRI Scans More Accurate
Clear medical scans help doctors see what's happening inside the body. But sometimes, these scans turn out blurry or unclear. That can make it hard for doctors to find small problems early. This is where Artificial Intelligence (AI) tools are making a big difference. These AI Tools can check images like MRI and CT scans in real-time and make sure the quality is good before the patient even leaves the room. AI tools are now being used in many hospitals to help doctors catch issues faster, avoid repeat scans, and follow global quality standards. Whether it's a chest CT or a prostate MRI, AI makes the scanning process smoother and more accurate. One such tool is AI‑QUAL by Quibim, a Spanish health-tech company. It checks prostate MRI images and tells the radiologist if the scan meets global quality rules. This means better care for patients, less waiting, and more confidence in the results. What is AI‑QUAL? AI‑QUAL is a smart tool that helps doctors check the quality of prostate MRI scans. It works like an assistant that looks at the images and makes sure they are clear and correct. If something is missing or blurry, it gives a quick warning so the team can fix it right away. This tool was made by Quibim, a health-tech company based in Spain. They added AI‑QUAL to their special platform called QP‑Prostate, which is already used for prostate imaging. The goal is to help doctors get the best possible images, without wasting time or asking patients to come back for another scan. AI‑QUAL follows a global quality rule called PI‑QUAL version 2. This rule tells doctors what a good prostate MRI should look like. By using AI‑QUAL, hospitals and clinics can follow these standards easily and give patients faster, more reliable results. How AI‑QUAL Works AI‑QUAL works quietly in the background during prostate MRI scans. As the images are taken, the tool checks them one by one. It looks for small problems—like missing angles, unclear spots, or wrong settings. If something isn't right, it sends an alert to the radiology team right away. The smart part? It uses a system called PI‑QUAL v2, which is a global guideline for prostate MRI quality. This means AI‑QUAL knows exactly what a good scan should include. Doctors don't have to guess—they get quick, automatic feedback during the scan itself. That saves time and helps avoid repeat scans later. AI‑QUAL is fully built into Quibim's QP‑Prostate platform, so it fits smoothly into the daily work of hospitals and clinics. Instead of slowing things down, it makes the process faster and more reliable. In short, it acts like an extra pair of expert eyes—always on, always checking, always ready to help. Key Benefits for Users 1. Doctors and Radiology Teams Fast, automatic checks. AI-QUAL scores each prostate MRI in seconds, so doctors spot low-quality images right away. AI-QUAL scores each prostate MRI in seconds, so doctors spot low-quality images right away. Fewer blind spots. The tool flags common issues—like metal streaks or gas bubbles—that can hide tumors. The tool flags common issues—like metal streaks or gas bubbles—that can hide tumors. Clear next steps. A simple 'pass / retake' alert guides technologists to fix problems on the spot. No guessing, no long wait. A simple 'pass / retake' alert guides technologists to fix problems on the spot. No guessing, no long wait. More confidence. Radiologists start reading with sharper scans, which helps them trust their findings and report faster. Quick check: When was the last time your team lost minutes debating scan quality? AI-QUAL makes that question disappear. 2. Patients and Families One visit, one scan. Good images the first time mean fewer callbacks and less travel. Good images the first time mean fewer callbacks and less travel. Earlier answers. Clear pictures let doctors see small cancers sooner, which can lead to quicker treatment. Clear pictures let doctors see small cancers sooner, which can lead to quicker treatment. Lower stress. No extra appointments, no extra prep—just a smoother experience from start to finish. 3. Hospitals and Clinics Standardized quality. AI-QUAL follows the PI-QUAL v2 rules, so every scan meets the same global benchmark. AI-QUAL follows the PI-QUAL v2 rules, so every scan meets the same global benchmark. Time saved. Automated scoring removes manual checks and frees staff for patient care. Automated scoring removes manual checks and frees staff for patient care. Better workflow. Fewer retakes keep MRI rooms moving and improve daily throughput. Fewer retakes keep MRI rooms moving and improve daily throughput. Reputation boost. Consistent, high-quality imaging builds trust with referring doctors and patients alike. 4. Health Systems & Researchers Reliable data. Consistent images make clinical trials cleaner and AI training sets stronger. Consistent images make clinical trials cleaner and AI training sets stronger. Cost control. Cutting unnecessary repeat scans reduces energy use, staff time, and overall imaging costs. Use Cases & Real-Life Examples 1. Busy Hospitals with High MRI Volume In many large hospitals, radiology teams handle dozens of MRI scans every day. Sometimes, due to time pressure, a low-quality scan slips through. With AI‑QUAL, that changes. For example, if a technician misses an important view during a prostate scan, the tool immediately detects it and asks for a retake—before the patient leaves the room. This saves time, avoids rescheduling, and speeds up diagnosis. 2. Small Clinics with New Staff Smaller clinics or centers with new MRI staff often face training challenges. AI‑QUAL acts like a helpful coach. It checks every scan and gives instant feedback. This means even junior technicians can follow best practices and deliver high-quality images, right from day one. It helps build confidence and maintain professional standards. 3. Research Centers and Clinical Trials Medical researchers rely on clean, consistent images when studying new treatments or testing new technologies. If one scan in a clinical trial is blurry or incomplete, it could affect the results. That's why some research hospitals are using AI‑QUAL to make sure every scan meets the same quality level. This makes the data more trustworthy and easier to analyze. Disadvantages and Limitations of AI‑QUAL While AI‑QUAL is a helpful tool, it's not perfect. Like any new technology, it comes with a few challenges that clinics and hospitals should keep in mind. 1. It doesn't replace human judgment AI‑QUAL checks image quality, not medical results. It won't spot cancer or give a diagnosis. Doctors still need to review each scan carefully. Over-relying on AI might cause people to skip important double-checks. 2. Works only with prostate MRI Right now, AI‑QUAL is designed just for prostate MRI scans. That means it doesn't help with other types of imaging like chest CTs, brain MRIs, or full-body scans. Clinics must use different tools for other exams. 3. Needs proper setup To use AI‑QUAL, you need Quibim's QP‑Prostate platform. This could mean new software installation, staff training, and possible updates to your current systems. Smaller clinics may find this a bit tricky or costly at first. 4. May not detect all issues While AI‑QUAL follows global quality rules, it still depends on the data it was trained on. In rare cases, it might miss unusual problems or give false alerts. That's why human review is always important. Expected Trends in the Future AI‑QUAL is a strong first step, but it's just the beginning. The future of this technology looks promising, with some exciting improvements likely coming soon. 1. Expanding Beyond Prostate MRI Right now, AI‑QUAL only works with prostate MRI scans. In the future, we may see Quibim expand this tool to cover other body parts—like brain, spine or liver MRIs. That would make the technology more useful across different departments in hospitals and imaging centers. 2. Smarter Feedback with Real-Time Guidance Today, AI‑QUAL checks the image and tells if it's good or not. But soon, it might also guide the technician step-by-step during the scan. For example, it could say: 'Tilt slightly left' or 'Scan missed the top area'—making scans better without needing a retake. 3. Combining AI-QUAL with Diagnosis Tools In the future, AI‑QUAL might work alongside tools that don't just check image quality but also help detect tumors or disease signs right away. Imagine one smart system that says, 'Image looks good and here's something the doctor should see.' 4. Easier Use in Small Clinics As AI‑QUAL improves, it could become easier to install, cheaper to run, and more user-friendly for small clinics with fewer staff. This would help more communities benefit from high-quality imaging. 5. Better Reporting and Learning Future versions may come with dashboards showing scan quality trends over time. This can help hospitals train staff better, improve equipment use, and even reduce costs by avoiding repeat scans. Conclusion AI‑QUAL by Quibim is a big step forward in making prostate MRI scans more reliable. It uses smart technology to check image quality in real-time, helping doctors get clearer pictures and make better decisions. For patients, this means fewer repeat scans, faster results, and more peace of mind. While it has a few limits like working only with prostate MRI for now, its future looks bright. With time, we may see tools like AI‑QUAL used across more types of scans and in more hospitals, big and small. As medical imaging continues to grow, AI‑QUAL is leading the way toward a smarter, faster, and more accurate healthcare system. FAQs about AI-QUAL Here is the list of Frequently asked questions related to this amazing AI Tool: 1. How much does AI‑QUAL cost for a hospital or clinic? The exact cost of AI‑QUAL isn't listed online. Pricing usually depends on how many scans the hospital does and how big the imaging team is. Most AI tools like this charge either a yearly fee or a price per scan. Hospitals and clinics need to contact Quibim directly to get a custom quote based on their needs. 2. Is AI‑QUAL approved by medical authorities like the FDA? Yes. AI‑QUAL is part of Quibim's QP‑Prostate platform, which has received FDA 510(k) clearance in the U.S., CE marking in Europe, and UKCA approval in the UK. That means it's already allowed for clinical use in many countries. Still, every hospital should double-check with local health regulators before using the tool. 3. How accurate is AI‑QUAL compared to human radiologists? AI‑QUAL doesn't diagnose cancer—it only checks if the MRI image is clear and complete. It gives a score based on international standards (called PI‑QUAL v2). So far, there's no public data showing how well it performs compared to radiologists. Doctors still need to review all images, just like before. 4. Will it work with any MRI machine? Yes, in most cases. AI‑QUAL works with standard DICOM images, which are used by all major MRI machine brands. However, Quibim recommends doing a quick check during setup to make sure everything connects smoothly. 5. How long does it take to train staff? Training doesn't take long. Most technologists can learn the basics in half a day, and radiologists often get comfortable with it after just one session. If your hospital uses a custom setup, you might need a little extra time for staff orientation. 6. What happens to patient data and privacy? AI‑QUAL is designed with privacy and security in mind. It uses encrypted data and follows rules like HIPAA in the U.S. and GDPR in Europe. Patient images stay inside the hospital's system or a secure cloud. Only the quality score is shared on the screen where doctors read the scan. 7. Can AI‑QUAL be used for children? No. AI‑QUAL is built for adult prostate MRI scans only. It's not tested or approved for children. Pediatric imaging needs different tools and guidelines. 8. How does it handle tricky cases like metal implants? AI‑QUAL can detect issues like metal streaks, motion blur, or gas bubbles—things that can make images unclear. When it finds these problems, it asks for a quick retake of the scan. But doctors still decide if the new images are good enough. 9. Does it need an internet connection to work? Not always. AI‑QUAL runs locally at the hospital, so it can work even without the internet. But to get software updates and support from Quibim, it's helpful to have occasional internet access. 10. How often does it need updates or support? Like most software, AI‑QUAL gets updates for security and new features. Updates usually come every few months and can install automatically. Most hospitals also get a support contract when they buy the license, which covers help and maintenance. TIME BUSINESS NEWS
